DGX
Quest Diagnostics Incorporated NYSE Listed Dec 17, 1996$190.79
Mkt Cap $21.1B
52w Low $164.65
53.5% of range
52w High $213.50
50d MA $198.14
200d MA $186.76
P/E (TTM)
21.7x
EV/EBITDA
11.7x
P/B
2.9x
Debt/Equity
1.0x
ROE
13.9%
P/FCF
14.2x
RSI (14)
—
ATR (14)
—
Beta
0.65
50d MA
$198.14
200d MA
$186.76
Avg Volume
1.0M
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
500 Plaza Drive · Secaucus, NJ 07094 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21, 2026 | AMC | 2.37 | 2.50 | +5.5% | 205.04 | +0.2% | -0.5% | -2.7% | -4.3% | -4.1% | -4.9% | — |
| Feb 10, 2026 | AMC | 2.36 | 2.42 | +2.5% | 205.35 | +0.8% | +1.9% | +0.7% | +0.7% | +0.1% | -0.5% | — |
| Oct 21, 2025 | AMC | 2.50 | 2.60 | +4.0% | 184.64 | +0.1% | -1.9% | -0.8% | -1.3% | -2.4% | -3.4% | — |
| Jul 22, 2025 | AMC | 2.57 | 2.62 | +1.9% | 178.24 | +0.8% | -4.4% | -3.6% | -5.4% | -5.8% | -5.8% | — |
| Apr 22, 2025 | AMC | 2.15 | 2.21 | +2.8% | 172.84 | -0.0% | +0.4% | +1.8% | +0.5% | +2.2% | +3.3% | — |
| Jan 30, 2025 | AMC | 2.19 | 2.23 | +1.8% | 164.17 | -0.1% | -0.7% | -1.0% | -0.5% | +0.4% | -0.9% | — |
| Oct 22, 2024 | AMC | 2.26 | 2.30 | +1.8% | 157.47 | +1.5% | -0.2% | +0.3% | -1.5% | -1.0% | -1.0% | — |
| Jul 23, 2024 | AMC | 2.34 | 2.35 | +0.4% | 140.96 | +0.7% | +2.1% | +2.3% | +3.3% | +0.8% | +1.4% | — |
| Apr 23, 2024 | AMC | 1.86 | 2.04 | +9.7% | 136.70 | -0.5% | +0.6% | -0.9% | -1.8% | +2.0% | +1.1% | — |
| Feb 1, 2024 | AMC | 2.11 | 2.15 | +1.9% | 127.17 | -0.6% | -1.7% | -2.7% | -0.7% | +0.2% | -0.5% | — |
| Oct 24, 2023 | AMC | 2.19 | 2.22 | +1.4% | 123.58 | -1.4% | +1.5% | +6.2% | +3.3% | +4.7% | +5.3% | — |
| Jul 26, 2023 | AMC | 2.27 | 2.30 | +1.3% | 136.24 | -0.2% | -1.4% | -1.3% | -0.8% | -1.2% | -1.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | Barclays | Maintains | Overweight → Overweight | — | $205.04 | $205.37 | +0.2% | -0.5% | -2.7% | -4.3% | -4.1% | -4.9% |
| Apr 22 | UBS | Maintains | Neutral → Neutral | — | $205.04 | $205.37 | +0.2% | -0.5% | -2.7% | -4.3% | -4.1% | -4.9% |
| Apr 22 | Truist | Maintains | Hold → Hold | — | $205.04 | $205.37 | +0.2% | -0.5% | -2.7% | -4.3% | -4.1% | -4.9% |
| Apr 22 | Baird | Maintains | Neutral → Neutral | — | $205.04 | $205.37 | +0.2% | -0.5% | -2.7% | -4.3% | -4.1% | -4.9% |
| Apr 8 | Evercore ISI | Maintains | In Line → In Line | — | $196.81 | $196.18 | -0.3% | +1.0% | +0.5% | -2.7% | -2.0% | -1.3% |
| Feb 12 | Mizuho | Maintains | Outperform → Outperform | — | $209.32 | $211.80 | +1.2% | -1.2% | -1.2% | -1.8% | -2.4% | -3.3% |
| Feb 11 | Truist | Maintains | Hold → Hold | — | $205.35 | $207.04 | +0.8% | +1.9% | +0.7% | +0.7% | +0.1% | -0.5% |
| Feb 11 | Jefferies | Maintains | Buy → Buy | — | $205.35 | $207.04 | +0.8% | +1.9% | +0.7% | +0.7% | +0.1% | -0.5% |
| Feb 11 | UBS | Maintains | Neutral → Neutral | — | $205.35 | $207.04 | +0.8% | +1.9% | +0.7% | +0.7% | +0.1% | -0.5% |
| Feb 11 | Evercore ISI | Maintains | In Line → In Line | — | $205.35 | $207.04 | +0.8% | +1.9% | +0.7% | +0.7% | +0.1% | -0.5% |
| Feb 11 | Barclays | Maintains | Overweight → Overweight | — | $205.35 | $207.04 | +0.8% | +1.9% | +0.7% | +0.7% | +0.1% | -0.5% |
| Feb 10 | Citigroup | Maintains | Neutral → Neutral | — | $191.25 | $194.72 | +1.8% | +7.4% | +9.4% | +8.2% | +8.2% | +7.4% |
| Oct 27 | Piper Sandler | Maintains | Neutral → Neutral | — | $182.18 | $181.37 | -0.4% | -1.1% | -2.1% | -4.1% | -3.5% | -3.4% |
| Oct 22 | Barclays | Maintains | Equal Weight → Equal Weight | — | $184.64 | $184.88 | +0.1% | -1.9% | -0.8% | -1.3% | -2.4% | -3.4% |
| Oct 22 | Truist | Maintains | Hold → Hold | — | $184.64 | $184.88 | +0.1% | -1.9% | -0.8% | -1.3% | -2.4% | -3.4% |
| Oct 21 | Leerink Partners | Maintains | Outperform → Outperform | — | $190.41 | $195.08 | +2.5% | -3.0% | -4.9% | -3.8% | -4.3% | -5.3% |
| Oct 21 | Jefferies | Maintains | Buy → Buy | — | $190.41 | $195.08 | +2.5% | -3.0% | -4.9% | -3.8% | -4.3% | -5.3% |
| Oct 17 | Mizuho | Maintains | Outperform → Outperform | — | $186.82 | $187.61 | +0.4% | +1.4% | +1.9% | -1.2% | -3.0% | -1.9% |
| Oct 17 | UBS | Maintains | Neutral → Neutral | — | $186.82 | $187.61 | +0.4% | +1.4% | +1.9% | -1.2% | -3.0% | -1.9% |
| Oct 8 | Evercore ISI | Maintains | In Line → In Line | — | $181.89 | $181.52 | -0.2% | -0.5% | -0.2% | +1.2% | +0.5% | +1.9% |
| Oct 2 | Barclays | Maintains | Equal Weight → Equal Weight | — | $182.07 | $180.83 | -0.7% | -0.6% | -1.5% | -2.0% | -0.1% | -0.6% |
| Aug 25 | Baird | Downgrade | Outperform → Neutral | — | $180.23 | $177.22 | -1.7% | -0.9% | +0.1% | -0.3% | -0.6% | +0.8% |
| Jul 23 | UBS | Maintains | Neutral → Neutral | — | $178.24 | $179.63 | +0.8% | -4.4% | -3.6% | -5.4% | -5.8% | -5.8% |
| Jul 23 | Truist | Maintains | Hold → Hold | — | $178.24 | $179.63 | +0.8% | -4.4% | -3.6% | -5.4% | -5.8% | -5.8% |
| Jul 23 | Deutsche Bank | Maintains | Hold → Hold | — | $178.24 | $179.63 | +0.8% | -4.4% | -3.6% | -5.4% | -5.8% | -5.8% |
| Jul 22 | Jefferies | Maintains | Buy → Buy | — | $166.45 | $170.63 | +2.5% | +7.1% | +2.4% | +3.3% | +1.3% | +0.8% |
| Jul 18 | UBS | Maintains | Neutral → Neutral | — | $168.18 | $168.57 | +0.2% | -0.8% | -1.0% | +6.0% | +1.4% | +2.2% |
| May 6 | JP Morgan | Maintains | Neutral → Neutral | — | $177.57 | $177.15 | -0.2% | -0.8% | -0.6% | -0.9% | -0.3% | -0.9% |
| Apr 28 | Piper Sandler | Maintains | Neutral → Neutral | — | $173.76 | $174.68 | +0.5% | +1.7% | +2.7% | +2.6% | +2.0% | +2.4% |
| Apr 23 | Truist | Maintains | Hold → Hold | — | $172.84 | $172.77 | -0.0% | +0.4% | +1.8% | +0.5% | +2.2% | +3.3% |
| Apr 23 | Evercore ISI | Maintains | In Line → In Line | — | $172.84 | $172.77 | -0.0% | +0.4% | +1.8% | +0.5% | +2.2% | +3.3% |
| Apr 23 | Barclays | Maintains | Equal Weight → Equal Weight | — | $172.84 | $172.77 | -0.0% | +0.4% | +1.8% | +0.5% | +2.2% | +3.3% |
| Apr 23 | Baird | Maintains | Outperform → Outperform | — | $172.84 | $172.77 | -0.0% | +0.4% | +1.8% | +0.5% | +2.2% | +3.3% |
| Apr 9 | Mizuho | Maintains | Outperform → Outperform | — | $159.80 | $158.15 | -1.0% | +2.7% | +2.5% | +2.6% | +5.1% | +4.6% |
| Mar 20 | Baird | Maintains | Outperform → Outperform | — | $168.01 | $167.80 | -0.1% | -0.9% | -0.5% | -0.4% | -1.4% | -0.8% |
| Mar 4 | Citigroup | Downgrade | Buy → Neutral | — | $176.95 | $175.79 | -0.7% | -1.1% | -2.8% | -3.0% | -0.8% | -2.2% |
| Feb 4 | JP Morgan | Maintains | Neutral → Neutral | — | $162.47 | $162.28 | -0.1% | +0.5% | +1.5% | +0.1% | +0.1% | +1.7% |
| Feb 3 | Piper Sandler | Maintains | Neutral → Neutral | — | $163.10 | $161.84 | -0.8% | -0.4% | +0.2% | +1.1% | -0.3% | -0.3% |
| Feb 3 | Mizuho | Maintains | Outperform → Outperform | — | $163.10 | $161.84 | -0.8% | -0.4% | +0.2% | +1.1% | -0.3% | -0.3% |
| Feb 3 | UBS | Maintains | Neutral → Neutral | — | $163.10 | $161.84 | -0.8% | -0.4% | +0.2% | +1.1% | -0.3% | -0.3% |
| Jan 31 | Barclays | Maintains | Equal Weight → Equal Weight | — | $164.17 | $163.94 | -0.1% | -0.7% | -1.0% | -0.5% | +0.4% | -0.9% |
| Jan 31 | Truist | Maintains | Hold → Hold | — | $164.17 | $163.94 | -0.1% | -0.7% | -1.0% | -0.5% | +0.4% | -0.9% |
| Jan 6 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $151.92 | $152.46 | +0.4% | +0.2% | +1.1% | +1.4% | -0.1% | +1.4% |
| Dec 23 | Mizuho | Maintains | Outperform → Outperform | — | $153.10 | $152.33 | -0.5% | -0.1% | +0.2% | -0.1% | -0.3% | -1.4% |
| Dec 17 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $152.65 | $153.19 | +0.4% | +1.9% | -0.9% | -0.7% | +0.3% | +0.2% |
| Dec 13 | BofA Securities | Maintains | Buy → Buy | — | $156.07 | $156.10 | +0.0% | -0.7% | -2.2% | -0.4% | -3.1% | -2.9% |
| Oct 28 | Piper Sandler | Maintains | Neutral → Neutral | — | $155.04 | $155.68 | +0.4% | +0.6% | +0.6% | +0.6% | -0.1% | +0.2% |
| Oct 24 | Mizuho | Maintains | Outperform → Outperform | — | $157.12 | $157.59 | +0.3% | +0.6% | -1.3% | -0.8% | -0.7% | -0.8% |
| Oct 23 | Baird | Upgrade | Neutral → Outperform | — | $157.47 | $159.84 | +1.5% | -0.2% | +0.3% | -1.5% | -1.0% | -1.0% |
| Oct 23 | Citigroup | Maintains | Buy → Buy | — | $157.47 | $159.84 | +1.5% | -0.2% | +0.3% | -1.5% | -1.0% | -1.0% |
No insider trades available.
8-K
Quest Diagnostics Inc. -- 8-K Filing
Quest Diagnostics reported over 9% organic revenue growth and 13% adjusted EPS growth in Q1 2026, demonstrating strong execution and expanding profitability despite a competitive diagnostic services market.
Apr 21
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Leadership transitions can signal strategic shifts or governance changes; investors should monitor whether this executive change strengthens management quality and operational execution to justify current valuation multiples.
Mar 12
8-K · 1.01
!! High
Insight Molecular Diagnostics Inc. -- 8-K 1.01: Material Agreement
Insight Molecular Diagnostics partnered with Quest Diagnostics through a specimen collection agreement, potentially expanding IMDX's diagnostic reach and revenue streams via Quest's extensive laboratory network.
Feb 26
8-K · 8.01
!! High
Quest Diagnostics Inc. -- 8-K 8.01: Material Event / Announcement
Quest Diagnostics increased its quarterly dividend by 7.5%, signaling management confidence in stable cash flows and returning more capital to shareholders.
Feb 10
Data updated apr 25, 2026 5:06am
· Source: massive.com